Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ST-067 + Teclistamab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ST-067 | ST067|ST 067|Vevoctadekin | ST-067 is a modified version of IL-18, which activates the IL-18 receptor, potentially leading to enhanced antitumor immune response (NCI Thesaurus). | ||
Teclistamab | Tecvayli | JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957 | CD3 Antibody 99 TNFRSF17 Antibody 20 | Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06588660 | Phase I | ST-067 + Teclistamab | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |